SLC1A2 and epilepsy: Targeting excitatory amino acid transporter 2 (EAAT2), the major glutamate transporter in the CNS, is a novel approach for developing epilepsy therapy (Ngomba and van Luijtelaar, 2018; Green et al., 2021).